Researchers explored data from nearly 70,000 patients, sharing their findings in the American Journal of Cardiology.

"I wasn’t expecting these results among women in this lower age group, because we usually see increased risk for heart disease among older women," one cardiologist said. "It was definitely surprising.”

Cardiologists now have two more tools to help them combat PAH, a rare vascular condition that often leads to heart failure.

While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things. 

This new approach to transplanting deceased after circulatory death (DCD) hearts may offer significant benefits.

Some of the world’s biggest names in interventional cardiology and structural heart disease gathered in Washington, D.C., for the four-day event. 

The portable device uses HeartBeam's patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthetic 12-lead ECG.

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing.